Here, we present a summary of the results of high throughput genetic, drug, miRNA, and profile screens performed on models of EGFR mutant NSCLC aimed at determining factors that positively or negatively affect mutant EGFR signaling dependence and a summary of the genetic changes that commonly co-occur with mutant EGFR in TKI-naïve patients (Figure 3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.